Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisAxitinib for the management of metastatic renal cell carcinomaVandetanib as a potential new treatment for estrogen receptor-negative breast cancers.MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsA Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity PredictionA Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.Integration of biomarkers including molecular targeted therapies in head and neck cancer.Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Development of the rat model of lapatinib-induced diarrhoea.YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical modelsAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Targeted therapies for gastric cancer: current status.ZD6474 coerces breast cancer for an apoptotic journeyExploring novel KDR inhibitors based on pharmaco-informatics methodology.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancerUtility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.Detection of cell aggregation and altered cell viability by automated label-free video microscopy: a promising alternative to endpoint viability assays in high-throughput screening.Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancerA systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesisZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxibIdentifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer modelIncidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.(3R,4S,5R)-Methyl 3,5-bis-[(tert-butyl-dimethyl-sil-yl)-oxy]-4-meth-oxy-cyclo-hex-1-ene-carboxyl-ateShared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.Novel agents for the treatment of adenocarcinoma of the pancreas.Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Targeting angiogenesis for treatment of human cancerEmerging EGFR antagonists for breast cancer.Vandetanib as a potential treatment for breast cancer.
P2860
Q22305863-7E15553E-FB09-48D1-A439-DE01F167C36EQ24613720-6CD33E41-1E34-41B1-B799-F9990627DB39Q27853297-486E8402-C99B-4E43-A36A-F4CA60AC4984Q28551045-D54CE9FA-352E-4B57-ADFF-39D1CE3D8EC3Q28551596-FA89C7F6-B2E5-4836-95DD-381CCBF68A56Q30300114-011859A5-0CB0-4F18-827D-00C386B93181Q30428632-83063177-0424-48B3-BFE1-104DC534ECE9Q33674090-BDDFBDB0-39E3-42B7-8D6A-5AD71887FB2FQ33923405-6D8E31CA-8C7A-4567-8298-FC2126E1CAD9Q33999288-6EE3CF0E-18CF-430A-BA48-6841017851F5Q34030791-6ECE5DB9-41AC-4882-90C8-1CD971569298Q34088265-0257FE1E-1913-48BC-BD84-85ACD1FB53E6Q34094154-3E5881AE-05E5-4EA3-A2A2-E2C7259014D5Q34205672-EFE7A191-F817-4CDC-96C7-A570ED7905C8Q34440490-31B472CB-F3AA-4C11-A83D-E6082F86B992Q34600778-06E21122-F75E-4C85-AD47-91C30B34FE05Q34616440-111FD64C-0180-4EC6-B4B8-818B255F730DQ35070321-77CF7F2B-2FE0-44AE-9E5D-2958040723E1Q35171274-FE574394-02A6-4D8D-80E4-52FFC3A1A4ECQ35177011-E0F0E998-01AB-4010-B482-7D2354EF7008Q35233993-D1F8C673-1A4F-48C7-AF54-9B6A02D50883Q35376241-53D4CBA9-1462-472E-A857-764694B8C9AFQ35529109-A1CB0413-9419-42BC-8CDE-FBE99BEB71CEQ35553791-FA82D7E8-AECF-47ED-AD19-357608CE1C8CQ35667802-FBEF8ACE-7825-4402-85A2-D4C52E5F7252Q35784523-52C756A3-7BB4-4052-B44C-C2ED35F6F82FQ36068707-D0EE722E-D04C-4239-90BF-B6F133253661Q36129640-7F8C6E00-A02F-4F4E-A909-1465FC0A6A3BQ36356334-284FB4ED-4972-4FF1-B2D6-61F8C99AB6FEQ36402044-AF7CF80A-4961-4152-ABD8-B06D2DDFF4A1Q36729895-0383DB32-F9E2-4459-B16C-4BEFBFDEEA60Q36738945-4C466AD3-9590-4E78-832C-EAB91DDDFE81Q36826533-3464EAEA-C3D0-415E-AA88-8147D128F875Q37117375-585BCD43-B500-4CFE-BB74-1A07E5380ECFQ37520154-3F505A6B-CA41-45AB-8421-6C2E667BDD0CQ37614590-74BBDC22-FDFE-4906-BDFC-D82820486D0CQ37760357-594507FA-87CB-4F8F-BD5D-BA6FB50BEE0DQ38125442-609F82FC-E435-4EF2-9A79-83CA4B3F4B1EQ38211951-B8CD0E2D-5D13-4160-908F-D8F28BE77926Q38236623-CA09C004-1893-4A7B-8232-7FF61B0AED61
P2860
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vandetanib (ZD6474), a dual in ...... status and future directions.
@en
Vandetanib (ZD6474), a dual in ...... status and future directions.
@nl
type
label
Vandetanib (ZD6474), a dual in ...... status and future directions.
@en
Vandetanib (ZD6474), a dual in ...... status and future directions.
@nl
prefLabel
Vandetanib (ZD6474), a dual in ...... status and future directions.
@en
Vandetanib (ZD6474), a dual in ...... status and future directions.
@nl
P2093
P50
P1433
P1476
Vandetanib (ZD6474), a dual in ...... t status and future directions
@en
P2093
Antonia Del Giudice
Ermelinda De Maio
Fabiano Falasconi
Francesco Perrone
Gianfranco De Feo
Jane Bryce
Maria Carmela Piccirillo
P304
P356
10.1634/THEONCOLOGIST.2008-0261
P577
2009-04-06T00:00:00Z